SAN DIEGO, Sept. 8, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated today announced the receipt from AnGes MG, Inc., of a $2.5 million installment payment for the company’s ongoing Allovectin-7(r) Phase 3 metastatic melanoma trial. Through a series of cash payments and equity investments under a previously announced collaborative agreement, Vical has now received the full $22.6 million committed by AnGes prior to trial completion. The trial is expected to complete enrollment of the planned 375 subjects by year-end 2009.
